Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Sep 30, 2023 10:05am
197 Views
Post# 35663155

RE:RE:RE:RE:RE:RE:Adlai Nortye Ltd prices offering at US$23 per share

RE:RE:RE:RE:RE:RE:Adlai Nortye Ltd prices offering at US$23 per share Moondance: Trust can be gained or lost by the turn of a word or phrase. Saying that ONCY's last capital raise was primarily taken up by a "large healthcare institutional buyer" as ONCY's press release alluded to,  is the same as saying that Cannacord, which happens to be a large institutional buyer of healthcare company stocks, bought the deal to cover its large short position in the stock. And judging by ONCY 's current share price, the only "added shareholder value" is just an oxymoron as the only added value would seem to have flowed into Canaccord's coffers rather than to other shareholders. By all normal standards "added shareholder value" is more appropriately represented in the tangible appreciation of a company's stock price. 
<< Previous
Bullboard Posts
Next >>